U.S. Markets closed

Global Dermatology Drugs Market Forecast to 2022: Focus on Acne, Dermatitis, Psoriasis, Others - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--

The "Dermatology Drugs Global Market Forecast To 2022" report has been added to ResearchAndMarkets.com's offering.

Global Dermatology Drugs Market Forecast to 2022 provides strategists, marketers and senior management with the critical information they need to assess the global dermatology drugs market.

The dermatology drugs market consists of sales of dermatology drugs and related by entities (organizations, sole traders and partnerships) that produce dermatology drugs to treat skin diseases. This industry includes establishments that produce drugs to treat diseases such as rosacea, dermatitis, hyperhidrosis, androgenic alopecia, acne, microbial infections and other skin disorders.

Where is the largest and fastest growing market for the dermatology drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Dermatology Drugs market global report from the author answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography. It places the market within the context of the wider pharmaceutical drugs market, and compares it with other markets.

Asia Pacific was the largest region in the global dermatology drugs market, accounting for 36% of the market in 2018. North America was the second largest region accounting for 28% of the global dermatology drugs market. Africa was the smallest region in the global dermatology drugs market.

Pharmaceutical companies are offering new drugs referred to as immune modulators for the treatment of skin diseases such as eczema. Eczema is a chronic skin condition caused by the lack of skin proteins that results in inflammation and irritation in the skin. These drugs are used to externally treat the skin without changing the immune system of the body.

In addition, unlike topical steroids, these new medications do not cause thinning of the skin and breaking of superficial blood vessels. Tacrolimus (Protopic) and Pimecrolimus (Elidel) are major drugs available for the treatment of eczema.

Key Topics Covered:

1. Executive Summary

2. Report Structure

3. Dermatology Drugs Market Characteristics

3.1. Market Definition

3.2. Key Segmentations

4. Dermatology Drugs Market Product Analysis

4.1. Leading Products/ Services

4.2. Key Features and Differentiators

4.3. Development Products

5. Dermatology Drugs Market Supply Chain

5.1. Supply Chain

5.2. Distribution

5.3. End Customers

6. Dermatology Drugs Market Customer Information

6.1. Customer Preferences

6.2. End Use Market Size and Growth

7. Dermatology Drugs Market Trends And Strategies

8. Dermatology Drugs Market Size And Growth

8.1. Market Size

8.2. Historic Market Growth, Value ($ Billion)

8.2.1. Drivers Of The Market

8.2.2. Restraints On The Market

8.3. Forecast Market Growth, Value ($ Billion)

8.3.1. Drivers Of The Market

8.3.2. Restraints On The Market

9. Dermatology Drugs Market Regional Analysis

9.1. Global Dermatology Drugs Market, 2018, By Region, Value ($ Billion)

9.2. Global Dermatology Drugs Market, 2014 - 2022, Historic And Forecast, By Region

9.3. Global Dermatology Drugs Market, Growth And Market Share Comparison, By Region

10. Dermatology Drugs Market Segmentation

10.1. Global Dermatology Drugs Market, Segmentation By Type, 2014 - 2022, Value ($ Billion)

10.1.1. Acne

10.1.2. Dermatitis

10.1.3. Psoriasis

10.1.4. Others

11. Dermatology Drugs Market Metrics

11.1. Dermatology Drugs Market Size, Percentage Of GDP, 2014 - 2022, Global

11.2. Per Capita Average Dermatology Drugs Market Expenditure, 2014 - 2022, Global

Companies Mentioned

  • Johnson & Johnson
  • Allergan Plc
  • Galderma S.A
  • Novartis AG
  • GlaxoSmithKline Plc

For more information about this report visit https://www.researchandmarkets.com/r/cgv3m8

View source version on businesswire.com: https://www.businesswire.com/news/home/20191204005568/en/